If mutations in a given gene or pathway are seen in a large enough fraction of a given tumor histology, it brings attention to that gene/pathway as having a possible critical role in the disease under study—with BCR-ABL in CML and BRAF in melanoma the two best examples [46, 47]. This evidence concerns the gene ABL1 and neoplasm.